

**Title:** Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19.

**Authors:** Nicola Gaibazzi, MD, PhD, Domenico Tuttolomondo MD, Angela Guidorossi MD, Andrea Botti MD, Andrea Tedeschi MD, Chiara Martini RT, Maria Mattioli MD.

**Corresponding Author:** Nicola Gaibazzi, MD, PhD, Department of Non-invasive Cardiology, Parma University Hospital, Via Gramsci 14, Parma 43126, Italy

Telephone number +39 0521 704962  
Fax number +39 0521 702189  
E-mail address [ngaibazzi@gmail.com](mailto:ngaibazzi@gmail.com)

**Total word count:** 732

There is currently little information regarding the role of active smoking in predisposing to SARS-CoV-2 infection.

Basic science suggests that higher angiotensin converting enzyme (ACE-2) concentration in the tissues of smokers may predispose to infection, but in fact the role of ACE-2 in COVID-19 is far from being understood (1).

The few published studies including smoking rates in patients with COVID-19 in their reports actually point right to the opposite direction; in fact, in the Chinese population the prevalence of smokers among COVID-19 patients has been reported between 1.4% and 12.6% (2-4), and also the very recent data coming from the New York City outbreak confirm a low prevalence of smokers in COVID-19 patients, in this case at 5.1%. (5)

These prevalence figures are so much lower than the respective national smoking rates (in China 24.7%, and in US 17.25% (<https://worldpopulationreview.com/countries/smoking-rates-by-country>) that suggest it is worth to further investigate whether there is an inverse association between smoke and predisposition to SARS-CoV-2 infection.

This retrospective case series includes 441 patients with confirmed Covid-19, who were consecutively admitted between March 5 and March 31, 2020, at a tertiary referral center in Parma, Northern Italy. Cases were confirmed through reverse-transcriptase–polymerase-chain-reaction assays, performed on nasopharyngeal swab specimens. Demographic information, laboratory, clinical variables and in-hospital mortality were collected during hospital stay and manually extracted from electronic health records; supplementary efforts were made to directly contact patients (or their relatives) to confirm the smoking status reported in the charts (423 out of 441 patients/relatives were actually successfully reached by phone).

This observational study was approved by the institutional review board of Parma University Hospital (371/2020/OSS/AOUPR). Informed consent was waived as part of the public health outbreak investigation.

441 patients (Table 1) formed the final study group of consecutive laboratory-confirmed COVID-19 patients; 273 (62%) patients were males. Median age was 71 y/o, 156 patients (35%) died during hospitalization and 285 (65%) were discharged because clinically healed. 21 patients (5%) were active smokers and 44 (10%) were ex-smokers, while 376 (85%) were non-smokers.

**Table 1.** Demographics, Clinical and Laboratory Characteristics of Patients with COVID-19

Characteristic	No. (%)			P-value
	Total	Alive	Dead	
No. of patients	441	285 (64.6)	156 (35.4)	-
Male	273 (61.9)	161 (58.6)	112 (71.8)	0.002
Age, median [interquartile range], y	71 [18]	67 [20]	76 [10]	p=0.76*
Current Smoker	21 (4.8)	11 (3.9)	10 (6.4)	0.333
Prior Smoker	44 (10)	30 (10.5)	14 (9)	0.723
Non smoker	376 (85.3)	244 (85.6)	132 (84.6)	0.887
<i>Comorbidities</i>				
Hypertension	254 (57.6)	159 (55.8)	95 (60.9)	0.349
Diabetes	92 (20.9)	51 (17.9)	41 (26.3)	0.051
Prior cardiovascular disease	63 (14.3)	30 (10.5)	33 (21.2)	0.004
<i>Laboratory</i>				
D-dimer, median [interquartile range], ng/mL	863 [8749]	736 [730]	1172 [1597]	p<0.001*
C-Reactive Protein [interquartile range], mg/L	130 [158]	107 [138]	163 [148]	p<0.001*

Abbreviations: \*variables expressed as median (interquartile range) compared with Mann-Whitney U test.

Male sex, history of prior cardiovascular disease, D-dimer and C-reactive protein were significantly more prevalent or higher in the subgroup of 156 patients who died during hospital stay, compared with 285 patients discharged alive. There was on the contrary no significant difference regarding the prevalence of smokers in the two subgroups.

Italy is the European Country with the highest number of deaths from COVID-19. Based on the sources of data used in this study, 441 COVID-19 patients were admitted between 5 and 31 March 2020. Active smokers were only 21, this number corresponding to less than 5% prevalence of active smokers, which is disproportionately low compared with the 24% prevalence of smokers in the general Italian population ( $p < 0.001$ ) (<https://worldpopulationreview.com/countries/smoking-rates-by-country>). The very low prevalence of smokers in our COVID-19 cohort seemingly replicates the findings that can be extracted from descriptive tables in Chinese reports and also in the recent US report from New York City (2-5).

Patients admitted with COVID-19 to an Italian hospital heavily involved in the recent outbreak showed a disproportionately low prevalence of active smokers compared with the general population. Since the study is limited by lack of inclusion of asymptomatic patients, the suggestion of a low prevalence of active smokers in COVID-19 should be confined to symptomatic and hospitalized patients. Another limitation is that individual drug therapy data during hospital stay is not available, although this is not supposed to bias the smoking history prevalence, collected at admission.

The current study is useful since it suggests that smokers may carry some type of protective mechanism from *symptomatic* SARS-CoV-2 infection, although this should definitely be

confirmed in specifically-designed, controlled studies (2-5). Only speculations can be done regarding the mechanism leading to this lower prevalence of smokers among COVID-19 patients admitted to hospital. For example, the exposure to smoke has been shown to modulate immune and adaptive immune responses and reduce systemic levels of several immune/inflammation markers, when compared with never smokers. Thus, smoking could attenuate the normal defensive function of the immune system, which becomes tolerant of a continuous inflammatory insult, while the immune system of non-smokers may be more prone to a the SARS-CoV-2 hyperacute cytokine release syndrome. Whatever the mechanism, if this hypothetical protective effect in active smokers is finally confirmed, it could help unravel the underlying molecular mechanism predisposing to SARS-CoV-2 infection, then also potentially exploitable by newly-conceived targeted protective drugs.

**Funding/Support:** None.

**Conflict of Interest Disclosures:** None reported.

## References

- 1) Vaduganathan M, Vardeny O, Michel T, McMurray J JV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020 March 30 [E-pub ahead of print]; <https://doi.org/10.1056/NEJMsr2005760>.
- 2) Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 February 19 [E-pub ahead of print]; <https://doi.org/10.1111/all.14238>.
- 3) Huang C, Wang Y, Li X, et al. Clinical features of patient infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
- 4) Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 Feb 28, last updated 2020 March 6 [E-pub ahead of print]; <https://doi.org/10.1056/NEJMoa2002032>
- 5) Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. DOI: 10.1056/NEJMc2010419